---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-013498"
form_type: "8-K"
ticker: "ELV"
cik: "0001156039"
company_name: "Elevance Health, Inc."
filed_at: "2024-01-24T23:59:59+00:00"
generated_at: "2026-06-06T19:03:07.752929+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Elevance Health Q4 adj EPS $5.62 (+15.2% YoY); FY 2024 outlook above $37.10

## Summary
- Q4 GAAP diluted EPS $3.63 (+1.1% YoY); adjusted diluted EPS $5.62 (+15.2% YoY).
- Q4 operating revenue $42.5B, up 7% YoY; full-year revenue $170.2B, up 9.3% YoY.
- FY 2024 guidance: GAAP EPS >$34.29, adjusted EPS >$37.10; quarterly dividend raised 10.1% to $1.63.
- Medical membership 47.0M, down 570k YoY from Medicaid redeterminations; Health Benefits operating gain +14% for the year.
- Operating cash flow $8.1B in 2023; repurchased 5.8M shares for $2.7B during the year.

## SEC filing metadata
- accession: 0001193125-24-013498
- form_type: 8-K
- ticker: ELV
- cik: 0001156039
- company_name: Elevance Health, Inc.
- filed_at: 2024-01-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1156039/000119312524013498/0001193125-24-013498-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1156039/000119312524013498/d736006d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-013498
- JSON: https://secwatch.observer/filing/0001193125-24-013498.json
- Plain text: https://secwatch.observer/filing/0001193125-24-013498.txt

## Key facts
- Earnings Releases
  Elevance Health, Inc. reported FY 2023 results: revenue $170 billion, EPS $25.22.
  - Period: FY 2023
  - Revenue: $170 billion
  - EPS: $25.22
  - Result: reported results
  source text: FY 2023 operating revenue of $170 billion, up 9.3% from FY 2022 • 4Q 2023 GAAP diluted EPS 1 of $3.63, up 1.1% from 4Q 2022 and adjusted diluted EPS 2 of $5.62, up 15.2%; FY 2023 GAAP diluted EPS of $25.22, up 3.9% from FY 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1156039/000119312524013498/0001193125-24-013498-index.htm
- Earnings Releases
  Elevance Health, Inc. reported Q4 2023 results: revenue $42.5 billion, EPS $3.63.
  - Period: Q4 2023
  - Revenue: $42.5 billion
  - EPS: $3.63
  - Result: reported results
  source text: 4Q 2023 operating revenue of $42.5 billion, up 7.0% from 4Q 2022; FY 2023 operating revenue of $170 billion, up 9.3% from FY 2022 • 4Q 2023 GAAP diluted EPS 1 of $3.63, up 1.1% from 4Q 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1156039/000119312524013498/0001193125-24-013498-index.htm
- Earnings Releases
  Elevance Health, Inc. reported FY 2024 results: EPS greater than $34.29. Guidance initiated.
  - Period: FY 2024
  - EPS: greater than $34.29
  - Guidance: initiated
  - Result: guidance update
  source text: Projected FY 2024 GAAP diluted EPS and adjusted diluted EPS 2 of greater than $34.29 and $37.10 per share, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1156039/000119312524013498/0001193125-24-013498-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.